Table of Contents
1.1 List of Tables 15
1.2 List of Figures 24
2 Introduction 25
2.1 Lung Cancer Diagnostic Tests Overview 25
3 Products under Development 26
3.1 Lung Cancer Diagnostic Tests – Pipeline Products by Stage of Development 26
3.2 Lung Cancer Diagnostic Tests – Pipeline Products by Territory 27
3.3 Lung Cancer Diagnostic Tests – Pipeline Products by Regulatory Path 28
3.4 Lung Cancer Diagnostic Tests – Pipeline Products by Estimated Approval Date 29
3.5 Lung Cancer Diagnostic Tests – Ongoing Clinical Trials 30
4 Lung Cancer Diagnostic Tests – Pipeline Products under Development by Companies 31
4.1 Lung Cancer Diagnostic Tests Companies – Pipeline Products by Stage of Development 31
4.2 Lung Cancer Diagnostic Tests – Pipeline Products by Stage of Development 36
5 Lung Cancer Diagnostic Tests Companies and Product Overview 41
6 Lung Cancer Diagnostic Tests – Recent Developments 220
7 Appendix 540
Table 1: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 26
Table 2: Lung Cancer Diagnostic Tests - Pipeline Products by Territory 27
Table 3: Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 28
Table 4: Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 29
Table 5: Lung Cancer Diagnostic Tests - Ongoing Clinical Trials 30
Table 6: Lung Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 31
Table 7: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 36
Table 8: A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 41
Table 9: Onco 88 - Lung Cancer Diagnostic Tests - Product Status 41
Table 10: Onco 88 - Lung Cancer Diagnostic Tests - Product Description 41
Table 11: OncoStain 88 - Lung Cancer Diagnostic Tests - Product Status 42
Table 12: OncoStain 88 - Lung Cancer Diagnostic Tests - Product Description 42
Table 13: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 43
Table 14: ARCHITECT c4000 System - NSE Assay - Product Status 43
Table 15: ARCHITECT c4000 System - NSE Assay - Product Description 44
Table 16: ARCHITECT c8000 System - NSE Assay - Product Status 44
Table 17: ARCHITECT c8000 System - NSE Assay - Product Description 44
Table 18: ARCHITECT ci4100 Integrated System - NSE Assay - Product Status 45
Table 19: ARCHITECT ci4100 Integrated System - NSE Assay - Product Description 45
Table 20: ARCHITECT ci8200 Integrated System - NSE Assay - Product Status 45
Table 21: ARCHITECT ci8200 Integrated System - NSE Assay - Product Description 46
Table 22: ARCHITECT i1000SR System - NSE Assay - Product Status 46
Table 23: ARCHITECT i1000SR System - NSE Assay - Product Description 46
Table 24: ARCHITECT i2000SR Integrated System - Neuron-Specific Enolase Assay - Product Status 47
Table 25: ARCHITECT i2000SR Integrated System - Neuron-Specific Enolase Assay - Product Description 47
Table 26: PRAME Antigen Lung Cancer Assay - Product Status 47
Table 27: PRAME Antigen Lung Cancer Assay - Product Description 48
Table 28: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 49
Table 29: Diagnostic Assay - Lung Cancer Diagnostic Tests - Product Status 49
Table 30: Diagnostic Assay - Lung Cancer Diagnostic Tests - Product Description 49
Table 31: MCM Test - Lung Cancer Diagnostic Tests - Product Status 50
Table 32: MCM Test - Lung Cancer Diagnostic Tests - Product Description 50
Table 33: Aberystwyth University Pipeline Products & Ongoing Clinical Trials Overview 51
Table 34: Diagnostic Biomarker Test - Lung Cancer Diagnostic Tests - Product Status 51
Table 35: Diagnostic Biomarker Test - Lung Cancer Diagnostic Tests - Product Description 51
Table 36: Abnova Corp Pipeline Products & Ongoing Clinical Trials Overview 52
Table 37: Diagnostic Test - ACTN4 - Product Status 52
Table 38: Diagnostic Test - ACTN4 - Product Description 53
Table 39: Acobiom Pipeline Products & Ongoing Clinical Trials Overview 54
Table 40: Companion Diagnostic Test - Lung Cancer Diagnostic Tests - Product Status 54
Table 41: Companion Diagnostic Test - Lung Cancer Diagnostic Tests - Product Description 54
Table 42: Diagnostic/Prognostic Assay - Lung Cancer Diagnostic Tests - Product Status 55
Table 43: Diagnostic/Prognostic Assay - Lung Cancer Diagnostic Tests - Product Description 55
Table 44: Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview 56
Table 45: DiagnoLung - Product Status 56
Table 46: DiagnoLung - Product Description 56
Table 47: Predictive Diagnostic Test - Lung Cancer Diagnostic Tests - Product Status 57
Table 48: Predictive Diagnostic Test - Lung Cancer Diagnostic Tests - Product Description 57
Table 49: Prognostic Test - Lung Cancer Diagnostic Tests - Product Status 57
Table 50: Prognostic Test - Lung Cancer Diagnostic Tests - Product Description 58
Table 51: AIT Austrian Institute of Technology GmbH Pipeline Products & Ongoing Clinical Trials Overview 59
Table 52: Biomarker Assay - Lung Cancer Diagnostic Tests - Product Status 59
Table 53: Biomarker Assay - Lung Cancer Diagnostic Tests - Product Description 59
Table 54: Almac Diagnostic Services Ltd Pipeline Products & Ongoing Clinical Trials Overview 60
Table 55: Prognostic Test - Early Stage Lung Cancer Diagnostic Tests - Product Status 60
Table 56: Prognostic Test - Early Stage Lung Cancer Diagnostic Tests - Product Description 60
Table 57: Prognostic Test - NSCLC - Product Status 61
Table 58: Prognostic Test - NSCLC - Product Description 61
Table 59: ANGLE plc Pipeline Products & Ongoing Clinical Trials Overview 62
List of Figures
Figure 1: Lung Cancer Diagnostic Tests - Pipeline Products by Stage of Development 26
Figure 2: Lung Cancer Diagnostic Tests - Pipeline Products by Territory 27
Figure 3: Lung Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 28
Figure 4: Lung Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 29
Figure 5: Lung Cancer Diagnostic Tests - Ongoing Clinical Trials 30
【免責事項】
https://www.marketreport.jp/reports-disclaimer